Session Information
-
WCLC 2018
19th World Conference on Lung Cancer
Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada
Download PDF of the Abstract Book: Click Here.
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2391
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26
-
+
JCSE01 - Perspectives for Lung Cancer Early Detection
- 07:30 - 11:15
- 9/23/2018
- Location: Room 202 BD
- Type: Joint IASLC/CSCO/CAALC Session
- Track: Screening and Early Detection
-
+
JCSE01.12 - Discussant Oral Abstracts
10:45 - 11:00 | Presenter: Daniel S.W. Tan
- Abstract
No abstract available for this presentation
-
+
OA02 - Novel Therapies in ROS1, HER2 and EGFR
- 10:30 - 12:00
- 9/24/2018
- Location: Room 105
- Type: Oral Abstract Session
- Track: Targeted Therapy
-
+
OA02.01 - Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
10:30 - 10:40 | Presenter: Robert C. Doebele | Author(s): Myung-Ju Ahn, Salvatore Siena, Alexander Drilon, Matthew G Krebs, Chia-Chi Lin, Filippo G. De Braud, Thomas John, Daniel S.W. Tan, Takashi Seto, Rafal Dziadziuszko, Hendrick-Tobias Arkenau, Fabrice Barlesi, Christian Rolfo, Jürgen Wolf, Edna Chow-Maneval, Pratik S. Multani, Na Cui, Todd Riehl, Byoung Chul Cho
- Abstract
Loading...
-
+
PC04 - Targeted Therapy for NSCLC
- 15:15 - 16:45
- 9/24/2018
- Location: Room 106
- Type: Pro-Con Session
- Track: Targeted Therapy
-
+
PC04.05 - NGS/Whole Exome Sequencing for Routine Use
16:03 - 16:15 | Presenter: Daniel S.W. Tan
- Abstract
No abstract available for this presentation
-
+
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session)
- 16:45 - 18:00
- 9/24/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P1.16-07 - Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
16:45 - 18:00 | Presenter: Wan Ling Tan | Author(s): Min Huang, Sheenu Chandwani, Tun-Ying Hsu, Seng Chuen Tan, Daniel S.W. Tan
- Abstract
Loading...
-
+
OA12 - Novel Therapies in MET, RET and BRAF
- 15:15 - 16:45
- 9/25/2018
- Location: Room 106
- Type: Oral Abstract Session
- Track: Targeted Therapy
-
+
OA12.07 - Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
16:20 - 16:30 | Presenter: Geoffrey R. Oxnard | Author(s): Vivek Subbiah, Keunchil Park, Todd M. Bauer, Lori J Wirth, Vamsidhar Velcheti, Manisha Shah, Benjamin Besse, Valentina Boni, Karen L. Reckamp, Herbert H Loong, Lyudmila Bazhenova, Ben J Solomon, Daniel S.W. Tan, Jyoti Patel, Melissa L. Johnson, Anas Gazzah, Tony S. Mok, Steve Smith, Brian Tuch, Kevin Ebata, Edward Y Zhu, Michele M Nguyen, Xin Huang, Scott Cruickshank, S Michael Rothenberg, Alexander Drilon
- Abstract
Loading...
-
+
P2.13 - Targeted Therapy (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P2.13-21 - MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Xue Lin Kwang | Author(s): Dawn Lau, Audrey-Ann Liew, Yuan Ju, Edwin Lim, Gillianne G.Y. Lai, Rahul Nahar, Yvonne Teng, Khi Pin Chua, Jacob Alvarez, Ming Jie Lim, Hui Sun Leong, Fui Teen Chong, Darren Toh, Hong Sheng Quah, Lisda Suteja, Lan Ying Wang, Kiat Hon Lim, Wan-Teck Lim, Eng-Huat Tan, Wei Wei Zhai, Wai Leong Tam, N Gopalakrishna Iyer, Daniel S.W. Tan
- Abstract
Loading... -
+
P2.13-45 - SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
16:45 - 18:00 | Presenter: Lecia Sequist | Author(s): Pasi A Jänne, Frances A Shepherd, Rudolf M Huber, Jhanelle Elaine Gray, Enriqueta Felip, Maurice Pérol, Fred R. Hirsch, Daniel S.W. Tan, Kim Caliri, Sara Ghassemifar, Ben Wang, Walid Kamoun, Sergio Santillana, Vasileios Askoxylakis, J Marc Pipas
- Abstract
Loading...